Marshall Wace’s Aratana Therapeutics, Inc. PETX Stock Holding History

Marshall Wace’s Portfolio PETX Stock Details PETX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-162,672	Closed	-$997K	–	2236
2018 Q4	$997K	Buy	+162,672	New	+$993K	0.01%	918
2016 Q4	–	Sell	-45,255	Closed	-$424K	–	1202
2016 Q3	$424K	Buy	+45,255	New	+$376K	﹤0.01%	819
2015 Q2	–	Sell	-30,897	Closed	-$495K	–	1118
2015 Q1	$495K	Buy	+30,897	New	+$550K	0.01%	674

Other funds holding PETX

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Engaged Capital Newport Beach, California $303M AUM 2.09% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

GPGA

Grandeur Peak Global Advisors Salt Lake City, Utah $427M AUM 39.14% 1-Year Est. Return

Impax Asset Management Group London, United Kingdom $14.3B AUM 19.8% 1-Year Est. Return

Marshall Wace's PETX Position: Q1 2019 in Review

Marshall Wace sold out of Aratana Therapeutics, Inc. (PETX) in Q1 2019, closing a stake of 162,672 shares — an estimated $997K sold.

Marshall Wace first reported a position in PETX in Q1 2015 and held it in 3 quarters. The position peaked at $997K in Q4 2018. 104 funds tracked by Wall St. Rank hold PETX as of Q1 2019.

Marshall Wace reported no remaining Aratana Therapeutics, Inc. position as of Q1 2019 after selling out during the quarter.
Marshall Wace sold 162,672 Aratana Therapeutics, Inc. shares in Q1 2019, an estimated $997K.
Marshall Wace first reported a position in Aratana Therapeutics, Inc. in Q1 2015 and held it in 3 quarters.
Marshall Wace's Aratana Therapeutics, Inc. position peaked at $997K in Q4 2018.
104 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q1 2019.

Based on Marshall Wace's 13F filing for Q1 2019, filed 14 May 2019.